Clinical Trials Directory

Trials / Completed

CompletedNCT02141113

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).

Double-Blind, Randomized, Placebo-Controlled, Single- Center, Dose Optimization Study Evaluating Efficacy and Safety of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults Aged 18-65 Years With a Diagnosis of ADHD

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
26 (actual)
Sponsor
Rochester Center for Behavioral Medicine · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This is considered an investigator-initiated clinical research trial, which means that your study doctor is researching a particular medication (in this case a medication that is currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication is guanfacine hydrochloride. The hypothesis is that this medication could be used in adults with Attention Deficit/Hyperactivity Disorder who have not received satisfactory results with their current stimulant ADHD medication. The study drug is investigational for use in adults. Investigational means it has not been approved by the U.S. Food and Drug Administration (FDA) for use in adults.

Detailed description

The purpose of this study is to determine whether guanfacine hydrochloride used as an adjunct therapy (to subjects' current stimulant medication) would bring about a statistically significant improvement in AD/HD symptoms.

Conditions

Interventions

TypeNameDescription
DRUGGuanfacine Hydrochloride1. mg Guanfacine Hydrochloride (orally) 2. mg Guanfacine Hydrochloride (orally) 3. mg Guanfacine Hydrochloride (orally) 4. mg Guanfacine Hydrochloride (orally) 5. mg Guanfacine Hydrochloride (orally) 6. mg Guanfacine Hydrochloride (orally)
OTHERPlaceboPlacebo of matching mg

Timeline

Start date
2012-11-01
Primary completion
2014-09-01
Completion
2014-11-01
First posted
2014-05-19
Last updated
2025-08-12
Results posted
2025-08-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02141113. Inclusion in this directory is not an endorsement.